Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11942583 | 0.89 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL12223952 | 0.85 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL10303345 | 0.85 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL11939001 | 0.81 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL11938890 | 0.79 | ADRA2A (0.36) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL10091422 | 0.79 | CYP11B1 (0.36) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL11938904 | 0.78 | ADRA2A (0.35) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL12223289 | 0.78 | ADRA2A (0.35) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL10302991 | 0.78 | ADRA2A (0.33) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL12223565 | 0.78 | ADRA2A (0.35) | ADRA2AADRA2BADRA2CADRA1AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
| EP-2266941-A1 | TRICYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | Chisso Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | ADRA2A 2131/4885ADRA2B 2601/4885ADRA2C 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.